not vested
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States.
Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity.
The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally.
http://todaysbigstock.com/2014/02/19/ac ... sdaq-acor/